Dana-Farber Cancer Insitute

Boston, Massachusetts 02215

2 studies enrolling now · 13 studies all time

What they study most

Advanced Breast Cancer, Advanced Lung Cancer, Breast Cancer, Chronic GVHD, Chronic Graft Versus Host Disease, Chronic Graft-versus-host-disease, Chronic Versus Graft Host Disease, Colon Adenocarcinoma, Complications of Organ Transplant Stem Cells, Graft Versus Host Disease, HER2 Mutation-Related Tumors, HER2-positive Advanced Breast Cancer

Studies at this site

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — Recruiting now
• STOP-HER2: Stopping Trastuzumab in HER2+ MBC — Running, not enrolling
• Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma — Enrolling by invitation
• Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML — Completed
• A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD — Completed
• Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease — Running, not enrolling
• Whole-Exome Sequencing (WES) of Cancer Patients — Completed
• Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD — Completed
• Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors — Completed
• Cardiac Fibrosis by CMR in Patients With Cancer — Withdrawn before enrolling
• Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant — Completed
• Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors — Completed
• Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer — Completed